Concepedia

Src Family Kinase Activity Is Up-Regulated in Hormone-Refractory Prostate Cancer

Oleg Tatarov, Thomas J. Mitchell, Morag Seywright, Hing Y. Leung, Valerie G. Brunton, Joanne Edwards

Clinical Cancer Research · 2009 · 153 citations · 23 references

DOIFull text

Open access

Abstract

Appropriate patient selection may allow better targeting of prostate cancer patients who are likely to respond to the treatment with SFK inhibitors at the same time improving the outcome of clinical trials.

References

23

Cancer Statistics, 2007

Ahmedin Jemal, Rebecca L. Siegel, Elizabeth Ward et al. · CA A Cancer Journal for Clinicians · 2007 · 7.5K citations · Full text

, , +13

Discovery of <i>N</i>-(2-Chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a Dual Src/Abl Kinase Inhibitor with Potent Antitumor Activity in Preclinical Assays

Louis J. Lombardo, Francis Y. Lee, Ping Chen et al. · Journal of Medicinal Chemistry · 2004 · 1.3K citations · Full text

, , +19

Steroid-induced androgen receptor-oestradiol receptor beta-Src complex triggers prostate cancer cell proliferation

Antimo Migliaccio · The EMBO Journal · 2000 · 659 citations · Full text

, , +7

Androgen receptor gene amplification and protein expression in hormone refractory prostate cancer

Joanne Edwards, N. Sarath Krishna, Ken Grigor et al. · British Journal of Cancer · 2003 · 426 citations · Full text

Action of the Src Family Kinase Inhibitor, Dasatinib (BMS-354825), on Human Prostate Cancer Cells

Sangkil Nam, Donghwa Kim, Jin Cheng et al. · Cancer Research · 2005 · 371 citations · Full text